WaVe Life Sciences Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 268

Employees

  • Stock Symbol
  • WVE

Stock Symbol

  • Share Price
  • $6.23
  • (As of Friday Closing)

WaVe Life Sciences General Information

Description

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Contact Information

Formerly Known As
Ontorii
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 733 Concord Avenue
  • Cambridge, MA 02138
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

WaVe Life Sciences Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.23 $6.48 $3.45 - $7.67 $763M 122M 662K -$0.52

WaVe Life Sciences Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 594,134 503,245 532,839 95,286
Revenue 112,914 113,305 3,649 40,964
EBITDA (53,398) (48,984) (154,542) (114,949)
Net Income (61,666) (57,513) (161,823) (122,245)
Total Assets 235,270 274,949 146,386 207,007
Total Debt 30,534 32,118 37,614 29,916
Public Fundamental Data provided by Morningstar, Inc. disclaimer

WaVe Life Sciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore WaVe Life Sciences‘s full profile, request access.

Request a free trial

WaVe Life Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ri
Drug Discovery
Cambridge, MA
268 As of 2023
00.000
00000000 00.000

0000 0

eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt i
0000 000000000
Waltham, MA
000 As of 0000
00.00
00000000 00.00

000000

llum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proi
0000000000000
Berkeley, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

WaVe Life Sciences Competitors (74)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dyne Therapeutics Formerly VC-backed Waltham, MA 000 00.00 00000000 00.00
Caribou Biosciences Formerly VC-backed Berkeley, CA 000 00000 00000000 00000
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland 000 00000 000000000 00000
Oligomerix Venture Capital-Backed White Plains, NY 00 00.000 0000000000 00.000
Minoryx Venture Capital-Backed Barcelona, Spain 00 00000 000000 - 000 00000
You’re viewing 5 of 74 competitors. Get the full list »

WaVe Life Sciences Patents

WaVe Life Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021471586-A1 Oligonucleotide compositions and methods of use thereof Pending 27-Oct-2021 0000000000
CA-3236136-A1 Oligonucleotide compositions and methods of use thereof Pending 27-Oct-2021 0000000000
US-20230392137-A1 Oligonucleotide compositions and methods thereof Pending 26-Sep-2021 0000000000
AU-2022349529-A1 Compositions for editing mecp2 transcripts and methods thereof Pending 26-Sep-2021 000000000
CA-3232070-A1 Oligonucleotide compositions and methods thereof Pending 26-Sep-2021 A61P1/16
To view WaVe Life Sciences’s complete patent history, request access »

WaVe Life Sciences Executive Team (10)

Name Title Board Seat Contact Info
Paul Bolno MD Chief Executive Officer & President
Kyle Moran Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Chandra Vargeese Ph.D Chief Technology Officer & Head of Platform Discovery Sciences
Anne Li-Kwai-Cheung Chief Development Officer
Erik Ingelsson Chief Scientific Officer
You’re viewing 5 of 10 executive team members. Get the full list »

WaVe Life Sciences Board Members (10)

Name Representing Role Since
Adrian Rawcliffe Self Board Member 000 0000
Christian Henry Self Chairman & Board Member 000 0000
Gregory Verdine Ph.D WaVe Life Sciences Board Member & Founder 000 0000
Heidi Wagner JD WaVe Life Sciences Board Member 000 0000
Ken Takanashi Shin Nippon Biomedical Laboratories Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

WaVe Life Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

WaVe Life Sciences ESG

Risk Overview

Risk Rating

Updated February, 16, 2024

33.47 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,191

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 452

Rank

00.00

Percentile

To view WaVe Life Sciences’s complete esg history, request access »

WaVe Life Sciences FAQs

  • When was WaVe Life Sciences founded?

    WaVe Life Sciences was founded in 2012.

  • Who is the CEO of WaVe Life Sciences?

    Paul Bolno MD is the CEO of WaVe Life Sciences.

  • Where is WaVe Life Sciences headquartered?

    WaVe Life Sciences is headquartered in Cambridge, MA.

  • What is the size of WaVe Life Sciences?

    WaVe Life Sciences has 268 total employees.

  • What industry is WaVe Life Sciences in?

    WaVe Life Sciences’s primary industry is Drug Discovery.

  • Is WaVe Life Sciences a private or public company?

    WaVe Life Sciences is a Public company.

  • What is WaVe Life Sciences’s stock symbol?

    The ticker symbol for WaVe Life Sciences is WVE.

  • What is the current stock price of WaVe Life Sciences?

    As of 14-Jun-2024 the stock price of WaVe Life Sciences is $6.23.

  • What is the current market cap of WaVe Life Sciences?

    The current market capitalization of WaVe Life Sciences is $763M.

  • What is WaVe Life Sciences’s current revenue?

    The trailing twelve month revenue for WaVe Life Sciences is $113M.

  • Who are WaVe Life Sciences’s competitors?

    Dyne Therapeutics, Caribou Biosciences, CRISPR Therapeutics, Oligomerix, and Minoryx are some of the 74 competitors of WaVe Life Sciences.

  • What is WaVe Life Sciences’s annual earnings per share (EPS)?

    WaVe Life Sciences’s EPS for 12 months was -$0.52.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »